Skip to main content
  • Contact Us
  • Vantage logo Sign Up
  • Subscriber Sign In
Evaluate Logo

navigation

  • COVID-19
    • COVID-19 Update
    • Evaluate Vantage COVID-19 Report
    • COVID-19 Stories from Evaluate Vantage
    • Evaluate’s Business Continuity Plan
  • What We Do
    • Commercial Intelligence
    • Products
      • Evaluate Pharma
      • Evaluate Omnium
      • Evaluate Epi
      • Japan Drug Forecasts
      • Europe Drug Forecasts
    • Evaluate Custom Solutions
    • Evaluate Vantage
      • News
      • Analysis
      • Policy & Pricing
      • Data Insights
      • Events
      • Medtech
      • Therapy Areas
      • Editorial Team
      • About Evaluate Vantage
    • Evaluate for Biotech
  • How We Can Help You
    • Pharma and Biotech
    • Medtech
    • Financial Services
    • Management Consultancies
    • Service Providers
    • Customer Testimonials
  • Thought Leadership
  • About Us
    • Press Releases
    • Media Coverage
    • Executive Team
    • Vision & History
    • Careers
      • Current Vacancies
  • Contact Us
  • Sign Up for Evaluate Vantage
  • Subscriber Sign In

 

Vantage logo

Vantage

  • Covid-19
    • Covid-19 Coverage
    • Evaluate Vantage COVID-19 Report
  • News
    • Snippets
    • Deals
    • Trial results
    • Patents and litigation
    • Corporate strategy
  • Analysis
    • Interviews
    • Spotlight
    • Vantage points
    • Vantage views
  • Data Insights
    • M&A
    • IPO
    • NME approvals
    • Quarterly shareprice performance
    • Venture financing
    • Vantage data points
    • Other data
  • Events
    • Company events
    • Conferences
    • Upcoming events
  • Medtech
  • Therapy Areas
  • About
    • Editorial team

Venture financing

Thumbnail
January 14, 2021

Medtechs rake in the venture cash

In terms of private investments, 2020 was the year of the liquid biopsy.

Thumbnail
January 07, 2021

Covid or not, venture financing breaks records

Private biotechs attracted more venture cash in 2020 than in any other year of the current cycle.

Article image
Vantage logo
October 28, 2020

Corporate investing plays an ever bigger role in medtech

The newest player in corporate financing, Intuitive, intends to deploy its fund with surgical precision.

Article image
Vantage logo
October 06, 2020

Hints of moderation emerge in biotech venture funding

Venture cash raised by private drug developers dipped slightly after two record-breaking quarters, but the party is far from over.

Article image
Vantage logo
July 14, 2020

Medtech venture investors live up to their name

Fortunately for medical device start-ups, it takes more than a pandemic to put venture capitalists off doing deals.

Article image
Vantage logo
July 10, 2020

Venture investors: biotech's preppers?

A handful of huge financings helped start-ups raise a record $5.4bn in the second quarter as investors brace for tougher times.

Article image
Vantage logo
April 08, 2020

Biopharma venture investors shrug off Covid-19

First-quarter venture investments barely register the pandemic - huge cash reserves should protect funding for biotech start-ups this year.

Article image
Vantage logo
January 16, 2020

Biopharma venture financing retreats, but not by much

Private drug developers raised less last year than in 2018, but cash remains plentiful and mega rounds abound.

Article image
Vantage logo
January 10, 2020

How low can medtech venture investment go?

2019’s medtech VC total is swollen by the sector’s first $1bn round, but counterintuitively the amount going to smaller groups is increasing.

Article image
Vantage logo
October 07, 2019

Venture cash gets even more concentrated

The latest venture capital numbers suggest that 2019 will see a healthy amount raised, but the falling number of rounds could be a worry.

Article image
Vantage logo
August 01, 2019

Private European companies enjoy their own treasure bath

The biotech financing scene in Europe continues to be dwarfed by the US, but on some measures the region is on an even footing.

  • Load More
We use cookies on this website. By using this site, you agree that we may store and access cookies on your device. Find out more.
Vantage logo
Independent, data-driven daily news and analysis on pharma, biotech and medtech.
Sign up

Latest Reports

February 11, 2021

Evaluate Vantage Pharma, Biotech & Medtech 2020 in Review

December 10, 2020

Evaluate Vantage 2021 Preview

View more...

Editor's Picks

Vantage logo
February 10, 2021

2020 wins top of the froths for biotech stocks

Vantage logo
October 04, 2018

Biotech flotations remain in high demand

Vantage logo
February 04, 2021

Glaxo’s growth problem

Vantage logo
January 27, 2021

Go or no go? Oncology decisions ahead for the FDA

Vantage logo
February 05, 2021

Pfizer reveals its PD-1 secret

Open modal

Evaluate HQ
44-(0)20-7377-0800

Evaluate Americas
+1-617-573-9450

Evaluate APAC
+81-(0)80-1164-4754

Footer menu

  • Terms and Conditions
  • Privacy Policies
  • Cookie Policy

© Copyright 2021 Evaluate Ltd.